| 名称 | PLX5622 |
| 描述 | PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor. |
| 体外活性 | METHODS: CX CR1+/GFP mouse-derived mixed glial cell cultures were treated with PLX5622 (0.1-10 µM) for 7 days and cell counts were assayed by Flow cytometry.
RESULTS: Although there was a dose-dependent decrease in microglia numbers under PLX5622, no decrease in GFAP+ astrocytes was seen, but rather a gradual increase, along with a decrease in PDGFR-a OPC. [1]
METHODS: Cerebellar sections prepared from PLP-eGFP mouse pups were treated with PLX5622 (1-20 µM) for 3 days followed by Immunostaining.
RESULTS: After three days of treatment, PLX5622 at concentrations greater than 2 µM eliminated more than 95% of microglia. [2] |
| 体内活性 | METHODS: To study in vivo activity, PLX5622 (1200 mg/kg) was administered to PLP eGFP mice by feed for 7-21 days.
RESULTS: PLX5622 was effective in depleting microglia in the central nervous system of adult mice. treatment with PLX5622 for 7 days had no effect on oligodendrocyte progenitor cell populations; however, a mild reduction was observed after 21 days in some central nervous system regions. [2] |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 16.67 mg/mL (42.15 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 7.9 mg/mL (19.98 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
|
| 关键字 | Inhibitor | CSF-1 receptor | microglial | PLX 5622 | CSF1R | orally | pathology | inhibit | c-Fms | penetrant | preceding | brain | colony stimulating factor 1 receptor | CSF-1R | elimination | PLX5622 |
| 相关产品 | c-Fms-IN-3 | c-Fms-IN-1 | Sotuletinib | Tandutinib | AZD7507 | Pazopanib Hydrochloride | GW2580 | Pexidartinib | c-Fms-IN-13 | Linifanib | Masitinib | Cerdulatinib hydrochloride |
| 相关库 | 高选择性抑制剂库 | 经典已知活性库 | 膜蛋白靶向化合物库 | 酪氨酸激酶分子库 | 激酶抑制剂库 | 药物功能重定位化合物库 | 抑制剂库 | 口服活性化合物库 | 已知活性化合物库 | 抗COVID-19化合物库 |
United States
